Extended Data Fig. 4: Overall survival according to biomarkers in the per-protocol population. | Nature Cancer

Extended Data Fig. 4: Overall survival according to biomarkers in the per-protocol population.

From: Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

Extended Data Fig. 4

N = 107 patients are included among which N = 98 with available CPS evaluation, N = 107 with HPV status and N = 77 patients with available TMB status. P-values from Log-rank test are reported. All statistical tests were two-sided. No adjustments were made for multiple comparisons. Median PFS for each population according to biomarkers are reported on the right of each graph.

Source data

Back to article page